Please login to the form below

Not currently logged in


This page shows the latest Biomarker news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

The same combination failed to move the needle in the MYSTIC trial, but signs of an improvement in a subgroup of patients with a particular cancer biomarker – high tumour mutational burden ... In a statement, AZ’s head of cancer R&D José Baselga

Latest news

More from news
Approximately 5 fully matching, plus 266 partially matching documents found.

Latest Intelligence

  • Rare disease trials Q&A Rare disease trials Q&A

    The selection of appropriate biomarkers and treatment outcomes. The design of clinical trials that can generate substantial efficacy and safety data and motivate patients.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Jean Georges Executive Director of Alzheimer Europe: “Preventing the development of dementia in biomarker-positive people would be a fantastic step forward in our fight against Alzheimer’s disease.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    However, the therapy wasn’t able to show an impact on biomarkers used to gauge the efficacy of MPS II drugs, and the company is now suggesting that it will have

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    A number of IO companies are pioneering the use of new biomarkers, eg tumour mutation burden (TMB). ... Thus, the continued search for new biomarkers is simply an evolution of the need to better understand and characterise neoplasias, and will invariably

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H).

More from intelligence
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • Diagnosing the lag in neuropsychiatric treatments

    The answer is simple, while bacterial and viral infections could be distinguished through characteristic biomarkers, reliable biomarkers for psychiatric diseases are almost non-existent.

  • Navigating the antibiotic resistance crisis

    Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating this complex landscape.

  • Three key development areas in the management of multiple sclerosis

    Mark and Fabrice identified three key themes across the meeting:. The use of neurofilament light chain (NfL) levels as a biomarker for disease activity and response to treatment– when neurons or ... Research presented at ECTRIMS shows promise for NfL

  • A4P Bio Consulting Ltd

    As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life sciences sector.

  • Is the pharma business model ready for precision medicine?

    It exists at the convergence of genomic sequencing, biomarker research, bioinformatics and big data analysis. ... This differs from traditional tumour type or ‘adaptive’ trials where the predictive biomarker is not clearly identified at trial

More from PMHub
Approximately 5 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....